BMEA · Biomea Fusion, Inc. · Metrics
$0.60
+0.02 (+2.58%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In connection with the preparation of this Quarterly Report on Form 10-Q for the period ended June 30, 2026, our management has concluded that there is substantial doubt as to whether we can continue as a going concern for the twelve months following the issuance of this Quarterly Report on Form 10-Q. Our ability to continue as a going concern is dependent upon raising capital to maintain current operations and continue research and development efforts. We plan to raise additional capital to fund our operations through public or private equity offerings, debt financings, and/or potential collaborations and license arrangement or other sources. There is no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed or that we will be able to obtain financing or enter into a collaboration on terms acceptable to us. Based on our current operating plan, we will not be able to continue as a going concern over the next twelve months unless we raise additional capital by other means. These factors raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 5, 2026
Market Cap
$43.50M
Shares
72.48M
Volume · Oct 23
958.01K
Avg daily vol (3M)
2.05M
BMEA metrics
61 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.60
Market cap
$43.50M
Price action
20 metricsPrice change (1W)
-30.9%
Price change (30D)
-59.7%
Price change (3M)
-52.0%
Price change (6M)
-68.2%
Price change (YTD)
-51.6%
Price change (1Y)
-56.5%
Trailing year
Price change (5Y)
-94.5%
52-week high
$2.21
52-week low
$0.59
Change from 52-week high
-72.8%
Change from 52-week low
+2.6%
Annualized volatility
91.6%
Annualized volatility (3M)
106.7%
Beta
1.5
RSI (14D)
22.6
Price vs SMA 50
-58.0%
Price vs SMA 200
-56.9%
Avg volume (3M)
2.05M
Relative volume
0.5
Average dollar volume
$2.83M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
72.48M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.6
reciprocal yield 27.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-74.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-10-13
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$58.06M
Net income (TTM)
−$32.54M
Trailing 12 months
Diluted EPS (TTM)
$-0.16
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+78.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-268.1%
Return on assets
-88.2%
Debt / equity
—
Current ratio
3.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$34.82M
Latest balance sheet
Cash & equivalents
$34.82M
Total assets
$36.87M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$47.19M
Capital expenditures (TTM)
$82,000
R&D (TTM)
$40.78M
SG&A (TTM)
—
Stock compensation (TTM)
$6.95M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
62
13F filer change QoQ
-3
Institutional ownership
36.1%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
12.2%
Private-fund adviser ownership
10.5%
Active holders' share change QoQ
+2.1%
Holder tenure
13.7
Price vs estimated holder cost
-82.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
5.0%
Short interest
3 metricsShort interest
19.4%
Latest settlement · 5.7 days to cover
Days to cover
5.7d
Short-squeeze score
75 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged